key: cord-0808369-ptstn9bt
authors: Mahajan, Shalini; Zhang, Felicia; Mahajan, Arjun; Zimnowodzki, Simon
title: Parsonage Turner syndrome after COVID‐19 vaccination
date: 2021-05-04
journal: Muscle Nerve
DOI: 10.1002/mus.27255
sha: 56b52b61092a915cd6997e5dad72f101bd82094f
doc_id: 808369
cord_uid: ptstn9bt

nan

significant neurological complications. 5 We describe a case report of PTS that developed a few days after administration of this vaccination. The overall incidence of PTS is estimated to be about 1 in 1000. 2, 6 The incidence of post vaccination PTS is not known, but is considered to be very rare. 

None of the authors have any conflict of interest to disclose.

The authors confirm that we have read the Journalʼs position on issues involved in ethical publication and effort them that this report is consistent with those guidelines.

The data that support the findings of this study are available from the corresponding author upon reasonable request. 

Lesion distribution among 281 patients with sporadic neuralgic amyotrophy

Neuralgic amyotrophy: an update on diagnosis, pathophysiology, and treatment

Natural history of brachial plexus neuropathy

Neuralgic amyotrophy following infection with SARS-CoV-2

Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine

Incidence of neuralgic amyotrophy (Parsonage Turner syndrome) in a primary care setting-a prospective cohort study

Public Health Service (PHS), Centers for Disease Control (CDC)/Food and Drug Administration (FDA), Vaccine Adverse Reporting System (VAERS) 1990-3/19/2021, CDC Wonder On-line Database